Tim Kipphan/Universität Bamberg

Project ‘IMMUNOVERSE’ launched as part of the DFG CRC 1755

As part of the DFG Collaborative Research Centre 1755 CASCAID, innovative new therapeutic approaches are being developed to sustainably halt chronic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel diseases. Building on these therapeutic advances, we are developing medical serious games that aim to enhance patients’ understanding of chronic inflammatory diseases and novel treatment options, while also making cutting-edge research more accessible to society.

Understanding complex medical concepts is often a major challenge. We believe that games can foster a better understanding of chronic diseases and emerging treatment options among patients and society at large.

Today, we are delighted and proud to announce that, as part of the recently funded DFG Collaborative Research Centre CASCAID, we are now able to conduct an in-depth exploration of the potential of digital games in patient and science communication.

Building on the latest research conducted by our colleagues at Universitätsklinikum Erlangen and FAU Erlangen-Nürnberg, we are developing serious games that aim to enhance patients’ understanding of autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel diseases, as well as innovative therapeutic approaches.

For us, these games are not only an innovative means of science communication but also serve as objects of scientific inquiry. In particular, we will examine the learning effects of such game-based formats and their potential influence on behavior, motivation, and decision-making. Furthermore, we will explore how the “Metaverse” can be leveraged for participatory science communication through the development of a virtual IMMUNOVERSE.

We very much look forward to the collaboration and the insights it will bring.

More information: 
https://www.uni-bamberg.de/games/forschung/dfg-sfb-1755-cascaid-seriousgames-und-immunoverse/ 
https://www.medizin3.uk-erlangen.de/forschung/arbeitgruppen/ag-s-jeleazcov/